Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern by Gernert, Michael et al.
RESEARCH ARTICLE Open Access
Autologous hematopoietic stem cell
transplantation in systemic sclerosis
induces long-lasting changes in B cell
homeostasis toward an anti-inflammatory B
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Abstract
Background: Autologous hematopoietic stem cell transplantation (aHSCT) is performed in patients with aggressive
forms of systemic sclerosis (SSc). The profile of B cell reconstitution after aHSCT is not fully understood. The aim of this
study was to investigate changes of B cell subsets and cytokine production of B cells in patients with SSc after aHSCT.
Methods: Peripheral blood of six patients with SSc was collected at defined intervals up to 16months after aHSCT.
Immunophenotyping was performed, and B cell function was determined by measuring cytokine secretion in
supernatants of stimulated B cell cultures.
Results: Within 1 month after aHSCT, a peak in the percentage of CD38++/CD10+/IgD+ transitional B cells and CD38+
+/CD27++/IgD− plasmablasts was detected. Long-term changes persisted up to 14months after aHSCT and showed an
increased percentage of total B cells; the absolute B cell number did not change significantly. Within the B cell
compartment, an increased CD27/IgD+ naïve B cell percentage was found whereas decreased percentages of CD27+/
IgD+ pre-switched memory, CD27+/IgD− post-switched memory, and CD27−/IgD− double-negative B cells were seen
after aHSCT. Cytokine secretion in B cell cultures showed significantly increased IL-10 concentrations 13 to 16months
after aHSCT.
Conclusion: A changed composition of the B cell compartment is present for up to 14months after aHSCT indicating
positive persisting effects of aHSCT on B cell homeostasis. The cytokine secretion profile of B cells changes in the long
term and shows an increased production of the immune regulatory cytokine IL-10 after aHSCT. These findings might
promote the clinical improvements after aHSCT in SSc patients.
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Background
Systemic sclerosis (SSc) is a heterogeneous and devastat-
ing autoimmune disease characterized by inflammation,
vasculopathy, and fibrosis. Fibrosis occurs in the skin
and the internal organs and is often refractory to stand-
ard immunosuppressive therapy [1]. Depending on the
extent of skin involvement, SSc can be divided into a
limited cutaneous form (lcSSc) or a diffuse cutaneous
form (dcSSc) [2]. SSc is the rheumatic disease with the
highest case mortality, mainly driven by pulmonary
hypertension and lung fibrosis [3]. The use of immuno-
suppressive therapy is restricted to patients with diffuse
progressive skin disease and progressive inner organ in-
volvement mainly of the lungs, whereas vasculopathy
can hardly be controlled by immunosuppressive therapy.
So far, studies have not been able to show that conven-
tional and biologic disease-modifying antirheumatic drugs
(DMARDs) have more than a limited effect on disease
manifestations; however, there is some evidence for the ef-
ficacy of mycophenolate mofetil and cyclophosphamide
[4, 5]. Case series suggest a slight benefit of rituximab to
skin and lung involvement [6, 7]. A phase 3-study investi-
gated the efficacy of tocilizumab in SSc patients and indi-
cates positive effects on lung fibrosis [8].
Of all treatment options for SSc autologous
hematopoietic stem cell transplantation (aHSCT) seems
to be the most efficacious therapy, but treatment toxicity
and treatment-related mortality have to be considered in
this population with limited organ function. Three ran-
domized trials (one unicenter, two multicenter) have
shown superior efficacy concerning skin and lung in-
volvement in patients with diffuse cutaneous SSc com-
pared to treatment with intravenous cyclophosphamide
once per month for 6 months [9] or intravenous cyclo-
phosphamide once per month for 12 months [10, 11].
The two multicenter trials also have shown a long-term
survival benefit, although early treatment-related mortal-
ity was increased [10, 11]. For aHSCT, patients’ stem
cells are mobilized using chemotherapy and granulocyte
colony-stimulating factor (G-CSF). These stem cells
were enriched by CD34+-selection and were reinfused
after an immunoablative conditioning regimen consist-
ing of cyclophosphamide and anti-thymocyte globulin
(ATG) in most cases. Nevertheless, relapses and disease
progression can occur also after aHSCT, and so far, there
are no studies that have examined treatment options
after aHSCT and few data is available about how aHSCT
evokes its effects.
The pathogenesis of SSc has been widely investigated.
Interstitial fibrosis is the major mechanism causing
organ damage. This fibrosis seems to be promoted by
disturbed T cell subsets [12, 13] and by secretion of
pro-fibrotic cytokines from CD8+ T cells [14]. Vasculop-
athy is correlated with specialized circulating angiogenic
T cells [15]. Furthermore, an altered B cell system has
been described demonstrating that B cells play an im-
portant role in the pathogenesis of SSc [16]: Auto-
immune properties of B cells are increased in SSc
patients by an overexpression of CD19 [17] and B cell
activating factor (BAFF) [18]. Plasma cells of SSc pa-
tients produce anti-topoisomerase 1/Scl70
auto-antibodies, which are associated with a more exten-
sive skin involvement [19], and alteration of B cell sub-
sets in SSc patients are described [20]. Disturbed
cytokine profiles in SSc patients are important in creat-
ing a pro-fibrotic state [21].
An important B cell subset in autoimmune diseases is
the CD19+/CD27−/IgD− (double-negative) B cell subset.
Although they do not express CD27, double-negative B
cells seem to belong to the memory compartment, as
their immunoglobulin receptors show somatic hypermu-
tations [22]. In rheumatoid arthritis (RA) and systemic
lupus erythematosus (SLE), double-negative B cells are
increased [23, 24]. In concordance with that, higher
numbers of double-negative B cells correlate with a bet-
ter response to rituximab in RA patients [25].
Interleukin (IL)-10 is a cytokine of special interest for
the investigation of the pathogenesis of SSc. IL-10 termi-
nates inflammatory processes and stimulates growth and
differentiation of various cell types including B cells, T
cells, NK cells, dendritic cells, and endothelial cells
among others [26]. Downstream the IL-10 receptor, the
signal transducer and activator of transcription 3
(STAT3) pathway and the phosphoinositide 3-kinase
(PI3K) pathway are activated, resulting in the inhibition
of antigen presentation and the inhibition of secretion of
pro-inflammatory cytokines mainly in macrophages and
dendritic cells [27]. That is why special attention was
turned to IL-10-producing B cells (Bregs) which can be
located within the CD19+/CD24high/CD38high or CD19+/
CD24high/CD27+ subpopulation [28]. A reduction of
Bregs [29] and a reduced ability to produce IL-10 is de-
scribed in SSc patients [30].
The aim of the present study was to elucidate the
changes in B cell subsets and in the B cell function in
SSc patients after receiving aHSCT. Those insights
might indicate treatment targets for SSc patients with
progressive or relapsing disease after aHSCT.
Patients and methods
Patients
Six patients (five female, one male; mean age 44.2 years,
range from 23 to 58 years) who met the ACR/EULAR
criteria [31] for SSc were included in the study. At the
time of aHSCT, five patients had a diffuse cutaneous
form (dsSSc) and one patient a limited cutaneous form
(lcSSc), two patients showed positivity for
Scl70-antibodies, and four patients had pulmonary
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fibrosis due to SSc. Patients’ characteristics are summa-
rized in Table 1.
We performed a prospective, non-interventional co-
hort study, which was approved by the local ethics com-
mittee. All patients gave their written informed consent.
Participation in this study had no influence on their
therapy.
Myeloablative autologous hematopoietic stem cell
transplantation
All patients suffered from progressive disease under con-
ventional immunosuppressive treatment and therefore
underwent aHSCT in the years 2014 to 2017. They re-
ceived a treatment protocol analogous to that used in
the ASTIS trial [10]: Patients received 2 g/m2 cyclophos-
phamide for mobilization of autologous hematopoietic
stem cells together with a minimum daily dose of 105 μg
granulocyte colony-stimulating factor (G-CSF), starting
on day 2 after cyclophosphamide, followed by leukapher-
esis. The autologous hematopoietic stem cells underwent
CD34+-selection using immunomagnetic separation
(CliniMACS CD34 Complete Kit, Miltenyi Biotec, Ber-
gisch Gladbach, Germany) in four out of six patients. In
two patients, stem cells were not CD34+-selected due to
low stem cell numbers in the leukapheresis product.
Then, patients obtained an immunoablative conditioning
regimen containing a total of 200 mg/kg cyclophospha-
mide (on days 1–4) plus 30 mg/kg rabbit ATG (on days
2–5). The autologous hematopoietic stem cells (mini-
mum dose of 2.0 × 106 CD34+ cells per kilogram body
weight) were then reinfused (on day 6).
Immunophenotyping
Peripheral blood was obtained before (range 5 to 12 weeks)
and after (at month 1, 2, 3, 5–7, and 12–14) aHSCT. Distri-
bution of B cell subsets was obtained from fresh blood via
immunophenotyping. Staining was performed with the
Navios cytometer (Beckman Coulter, Krefeld, Germany)
using the following antibodies: CD19-phycoerythrin-cyanin
(PC) 7, CD20-allophycocyanin (APC) 750, CD45-Krome
Orange, CD27-phycoerythrin-Texas Red-X (ECD),
CD38-PC5.5 (each Beckman Coulter, Krefeld, Germany),
IgD-fluorescein isothiocyanate (FITC), CD10-phycoerythrin
(PE) (each BD Biosciences, San Jose, CA), CD21-Pacific
Blue (Exbio, Prague, Czech Republic), and IgM-APC (Bio-
Legend, San Diego, CA). Lymphocytes were identified by
using forward versus sideward scatter. Within the lympho-
cyte gate, at least 3000 events were collected and CD19+
cells were identified as B cells. Transitional B cells were de-
fined as CD38++/CD10+/IgD+, pre-switched memory B cells
as CD27+/IgD+, post-switched memory B cells as CD27+/
IgD−, double-negative B cells as CD27−/IgD−, naïve B cells
as CD27-/IgD+, and circulating plasmablasts as CD38+
+/CD27++/IgD−.
Preparation of peripheral blood mononuclear cells
(PBMCs) and B cell enrichment
Peripheral blood in EDTA-tubes (15–20ml) was ob-
tained before (range 6 to 12 weeks) and after (range 13
to 16 months) aHSCT and processed with Ficoll-Paque
Plus separation (GE Healthcare, Munich, Germany) ac-
cording to the manufacturer’s instructions to receive
PBMCs. PBMCs were stored in liquid nitrogen before
they were incubated with CD19 monoclonal
antibody-coupled microbeads to separate B cells by mag-
netic cell sorting (MACS; Miltenyi Biotec, Bergisch
Gladbach, Germany). Each PBMC sample was loaded
onto two MACS columns successively to achieve a B cell
purity over 95%.
B cells cultures and cytokine measuring
The enriched B cells were incubated over 24 h with 10 μg/
ml cytosine guanine dinucleotide (CpG ODN 2006, Invi-
voGen, Toulouse, France) in 96-well plates at a concentra-
tion of 0.5–1 × 106 cells/ml. Supernatants were then
collected and stored at − 80 °C. Cytokines from superna-
tants of the B cell cultures were measured using cytomet-
ric bead array (CBA flex set; BD bioscience, San Jose, CA)
in a LSR II cytometer (BD bioscience, San Jose, CA). Con-
centrations of cytokines were calculated using FCAP array
software (BD bioscience, San Jose, CA).
Statistical analysis
Samples were tested for normal distribution by perform-
ing Shapiro-Wilk tests and Q-Q plots. If normal distri-
bution was determined, means ± standard deviations
Table 1 Characteristics of the study population*
Patient Sex Age at aHSCT Cutaneous form Scl-70 positivity Pulmonary fibrosis Troponin positivity CD34+-selected graft
1 F 38 dc + + – +
2 F 53 lc – – + +
3 M 58 dc – + + –
4 F 47 dc – + – +
5 F 23 dc + – + –
6 F 46 dc – + – +
*F female, M male, dc diffuse cutaneous form, lc limited cutaneous form
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(SD) were calculated and differences were analyzed using
a two-tailed paired t test. If normal distribution could
not be determined, medians with interquartile ranges
(IQR) were calculated and Wilcoxon signed-rank tests
were performed to detect differences between groups.
SPSS Statistics v 25.0 (IBM, Armonk, NY) and Excel
(Microsoft, Redmond, WA) were used. Differences were
considered significant when P values were less than 0.05.
Results
Increased percentage of total B cells after aHSCT
In the first month after aHSCT, the percentage of total B
cells within the lymphocyte gate showed the lowest
values (0.6 ± 0.5%; mean ± SD) compared to the baseline
values before aHSCT (6.8 ± 5.3%; P = 0.030). In that
stage of the lymphocyte repopulation, the predominant
population were NK cells (data not shown). Total B cell
percentages showed the highest values 20.7 weeks (range
10–47 weeks) after aHSCT. Total B cell percentages in-
creased significantly 4.2-fold from 6.8 ± 5.3% at baseline
to 28.5 ± 12.9% 3 months after aHSCT (P = 0.013). A sig-
nificant increase in total B cell percentages was main-
tained until 14 months after aHSCT (Fig. 1a). The
longest follow-up in one patient comprised 2 years and
showed a sustained 4.1-fold increase of the total B cell
percentage (4.8% at baseline compared to 19.5% 2 years
after aHSCT).
Absolute numbers of B cells had the lowest values
1 month after aHSCT and increased continuously over
time, starting from the second month after aHSCT,
without showing any significant changes compared to
baseline (Fig. 1b). Lymphocyte numbers (Fig. 1c) showed
a mean of 1478.3 ± 929.9/μl at baseline. The minimum
of lymphocyte numbers was detected 1 month after
aHSCT (605.0 ± 277.8/μl; P = 0.039). From month two
after aHSCT, lymphocyte numbers recovered and did
not show significant differences to baseline.
Early phase of B cell repopulation
The subset analysis within the B cell compartment re-
vealed a specific repopulation pattern after aHSCT. In
the first month after aHSCT, a 10-fold increase could be
detected in the percentage of plasmablasts (CD38+
+/CD27++/IgD−) from 2.8 ± 4.6% at baseline compared to
28.7 ± 22.7% 1 month after aHSCT (P = 0.040; Fig. 2a).
The absolute numbers of plasmablasts did not change
significantly after aHSCT (Fig. 2b). A 21-fold increase in
the percentage of transitional B cells (CD38++/CD10+/
IgD+) from 2.4 ± 3.2% at baseline compared to 50.8 ±
29.9% 1 month after aHSCT (P = 0.008) was present
(Fig. 2c). Absolute numbers of transitional B cells
showed a peak of 25.6 ± 10.7/μl 2 months after aHSCT
compared to baseline 1.6 ± 2.0/μl (P = 0.026; Fig. 2d).
Those changes diminished over time, with no significant
Fig. 1 Changes of B cell percentages (a), B cell numbers (b), and
lymphocyte numbers (c) after aHSCT. a B cell percentages within the
lymphocyte gate at different time points. Baseline (before aHSCT),
month 1, month 2, month 3, months 5–7, and months 12–14 after
aHSCT. b Corresponding B cell numbers/μl and c lymphocyte
numbers/μl at respective time points. n = 6 (except months 2 and 3
n = 5); mean ± SD; *significant (P < 0.05) difference compared to
baseline in the two-tailed paired t test
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differences in plasmablast and transitional B cell per-
centages and absolute numbers 1 year after aHSCT com-
pared to baseline.
Long-term changes in B cell subsets after aHSCT
Starting from 2 months after aHSCT, distinct changes in
the B cell subsets could be detected. The B cell repopu-
lation was mainly accomplished by naïve B cells
(CD27−/IgD+). Naïve B cell percentages increased sig-
nificantly 1.4-fold from 65.4 ± 13.2% at baseline to 91.9
± 3.9% 1 year after aHSCT (P = 0.004; Fig. 3a). Also, ab-
solute naïve B cell numbers showed a significant in-
crease from 88.9 ± 131.4/μl at baseline to 233.6 ± 127.7/
μl 1 year after aHSCT (P = 0.024; Fig. 3b).The memory B
cell compartment (CD27+) did not recover until 1 year
after aHSCT. The pre-switched memory B cell percent-
ages (CD27+/IgD+) declined from 9.1 ± 4.3% at baseline
to 3.1 ± 1.4% 1 year after aHCT (P = 0.029; Fig. 3c). Simi-
lar changes could be detected in the post-switched
memory B cells (CD27+/IgD−): Percentages declined
from 18.9 ± 11.4% at baseline to 3.1 ± 2.4% 1 year after
aHSCT (P = 0.023; Fig. 3e). Absolute numbers of
pre-switched (Fig. 3d) or post-switched memory B cells
(Fig. 3 f ) did not change significantly after aHSCT.
Double-negative B cell percentages (CD27−/IgD−)
showed a constant decrease after aHSCT (6.6 ± 3.2% at
baseline versus 2.0 ± 1.0% 1 year after aHSCT; P = 0.015;
Fig. 3g), whereas absolute numbers of double-negative B
cells showed no long-term changes (Fig. 3h).
Increased IL-10 secretion by B cells after aHSCT
To evaluate the influence of aHSCT on the B cell func-
tion of SSc patients, B cell cultures were stimulated with
CpG ODN and cytokines were measured in the superna-
tants. The effect of CpG ODN stimulation on the cyto-
kine secretion is described in Additional file 1: Figure
S1. B cells after aHSCT showed a higher secretion of
IL-10 compared to the levels before transplantation. The
median concentration of IL-10 before aHSCT was 0.8
pg/ml (IQR 0.0–2.5 pg/ml) versus 8.6 pg/ml (IQR 3.9–
Fig. 2 Changes of plasmablast (CD38++/CD27++/IgD−) percentages (a), plasmablast numbers/μl (b), transitional B cell (CD38++/CD10+/IgD+)
percentages (c), and transitional B cell numbers/μl (d) after aHSCT at respective time points. n = 6 (except month 2 n = 4 and month 3 n = 5);
mean ± SD; *significant (P < 0.05) difference compared to baseline in the two-tailed paired t test
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Fig. 3 (See legend on next page.)
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11.2 pg/ml) after aHSCT (P = 0.043). No significant
changes were observed in the secretion of the following
cytokines after aHSCT: IL-6, IL1-β, TNF-α, TGF-β,
IL-12/IL-23, and G-CSF (Fig. 4). No secretion of IL-1-α
could be detected (data not shown).
Improved skin involvement and stabilized lung function
of SSc patients after aHSCT
Clinical data was assessed before and 10 to 18months
after aHSCT. The mean modified Rodnan skin score
(mRSS) of the six SSc patients improved after aHSCT.
Before aHSCT, the mean mRSS was 21.8 ± 11.3 (mean
mRSS ± SD; range 9–41); after aHSCT, the mean mRSS
was 11.5 ± 7.3 (range 2–20; P = 0.005). The mean diffus-
ing capacity for carbon monoxide (DLCO) showed stable
values, which means no worsening of lung function. Be-
fore aHSCT, DLCO was 45.3 ± 20.7% (mean % of pre-
dicted DLCO ± SD), and after aHSCT, it was 47.5 ±
23.8% (P = 0.315). The mean forced vital capacity (FVC)
was stable over the course of the study. Before aHSCT,
it was 80.0 ± 19.1% (mean % of predicted FVC ± SD),
and after aHSCT, it was 88.3 ± 24.0% (P = 0.066). Mor-
phological pulmonary fibrosis, documented as interstitial
lung disease by thoracic computed tomography, showed
stable findings or even a decline in fibrotic manifesta-
tions after aHSCT.
Discussion
This prospective study analyzed the composition of the
peripheral B cell compartment and the cytokine profile
of purified B cells upon CPG stimulation of SSc patients
before and after aHSCT.
After aHSCT, an increased total B cell percentage
within the lymphocytes was seen. Within the B cell com-
partment, increased naïve B cells, decreased memory B
cells (pre- and post-switched), and decreased
double-negative B cells could be detected. Those
changes were long-term changes and stable at least until
1 year after aHSCT.
Similar repopulation patterns after aHSCT have been
reported in other autoimmune diseases, for example SLE
or multiple sclerosis with an incline in naïve B cell fre-
quencies and a decline in memory B cells [32, 33]. Also,
in hematologic malignancies, an increased naïve B cell
compartment after aHSCT was described [34].
The B cell repopulation pattern after aHSCT described
is similar to the repopulation after B cell depleting treat-
ment with rituximab. Application of rituximab caused a
long-lasting reduction of memory B cells [35], persisting
even after repeated treatment with rituximab in RA pa-
tients [36]. In contrast to the treatment with rituximab
after aHSCT, the total B cell percentage is increased
1 year after treatment. An increased percentage of total
B cells in absence of a change in the absolute numbers
of total B cells after aHSCT could be explained by the
previously described T cell lymphopenia, especially
CD4+ T cell lymphopenia, following aHSCT [37].
Our six patients achieved an improved mRSS and a
stabilized lung function after aHSCT, similar to other
cohorts [10]. To mediate these clinical improvements,
(See figure on previous page.)
Fig. 3 Naïve B cell (CD27-/IgD+) percentages (a) and naïve B cell numbers/μl (b), pre-switched memory B cells (CD27+/IgD+) percentages (c) and
pre-switched memory B cell numbers/μl (d), post-switched memory B cell (CD27+/IgD−) percentages (e) and post-switched memory B cell
numbers/μl (f), double-negative B cell (CD27−/IgD−) percentages (g) and double-negative B cell numbers/μl (h), at baseline and after aHSCT at
respective time points. n = 6 (except month 2 n = 4 and month 3 n = 5); mean ± SD; *significant (P < 0.05) difference compared to baseline in the
two-tailed paired t test
Fig. 4 Cytokine concentrations in CpG-stimulated B cell cultures (B cell purity over 95%) from SSc patients before (white boxes; n = 5) and 11–16
months after aHSCT (gray boxes; n = 6). Boxes show interquartile range and median, whiskers show the lowest or highest value; *P < 0.05 using
the Wilcoxon signed-rank test
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the aHSCT aims to accomplish a reset of the immune
system and of the B cell system [38]. A dysfunctional B
cell homeostasis is postulated to play an important role
in the pathogenesis of SSc [16]. aHSCT might evoke a
shift of the B cell homeostasis toward a regulatory
phenotype. As seen in this study, the secretion of the
immune regulatory cytokine IL-10 is significantly in-
creased after aHSCT. This could be explained by the re-
currence of regulatory B cells (Bregs) after aHSCT as
Bregs are often defined through their ability to produce
IL-10 and are known to be an important B cell popula-
tion producing IL-10 [39]. As we measured the IL-10
production in cultures of total B cells, we cannot distin-
guish which B cell subset mainly produced the detected
IL-10. IL-10 might not only originate from Bregs. As
naïve B cells are described to be important producers of
IL-10 [40], and we could show increased percentages
and absolute numbers after aHSCT, naïve B cells might
have contributed to a high extend to the IL-10 produc-
tion. Therefore, the increased IL-10 concentration might
be a reflection of the regenerating B cell system. The
production of IL-10 is not restricted to B cells, but B
cell-derived IL-10 seems to be very important in the
pathogenesis of SSc. This could be shown in a
bleomycin-induced mouse model. Mice with a B
cell-specific deficiency in the IL-10 production showed a
more severe skin and lung fibrosis, compared to mice
with sustained IL-10 production by B cells [41].
Administration of IL-10 to treat autoimmune diseases
has been studied extensively and led to a reduction of
psoriatic plaques in psoriasis and ameliorated the disease
activity in intestinal bowel disease [27, 42]. In contrast
to that, blocking IL-10 showed a significant clinical im-
provement in SLE patients in a small open-label study
[43]. Therefore, using IL-10 as a therapeutic agent seems
to be ambivalent due to its pleiotropic effects in different
autoimmune diseases.
SSc patients can show progressive disease manifesta-
tions after aHSCT. Plasma cells can survive in bone mar-
row niches despite cytoreductive or immunosuppressive
therapies [44], which could explain refractory disease or
relapse [45, 46] and could be one reason why even after
aHSCT further treatment is necessary. Data for treatment
after aHSCT in SSc patients is limited. As an increased B
cell percentage after aHSCT is present, one could specu-
late that the application of rituximab could be an effective
therapy. In two of our patients, rituximab was used suc-
cessfully without adverse effects after aHSCT due to pro-
gressive skin involvement. Application of rituximab
already has shown an improvement in the mRSS and sta-
bilized the lung function [6] or even improved the lung
function [7] of SSc patients.
Limitations of our study arise due to the relatively small
number of included patients. Further investigations of SSc
patients after aHSCT are necessary to support our
findings.
Conclusion
In summary, aHSCT causes distinct changes in the B cell
compartment with an increased B cell percentage and a
decreased memory B cell compartment. The predomin-
ant B cell subpopulation after aHSCT is naïve B cells.
After aHSCT, B cells show an increased secretion of the
immune regulatory cytokine IL-10. All of these changes
could play a role in the persisting clinical improvements
of SSc patients after aHSCT. Elevated total B cell per-
centages and changes in cytokine concentrations offer
possibilities for future treatments of progressive SSc
after aHSCT.
Additional file
Additional file 1: Figure S1. Toll-like receptor 9 stimulator CpG ODN
induces cytokine secretion in B cell cultures of SSc patients. B cell cultures
(two samples before aHSCT and four samples after aHSCT) from SSc
patients who were not treated with CpG (no CpG; white boxes) or were
treated with CpG (10 μg/ml; gray boxes). The cytokine concentrations in the
supernatants were measured. A significant increase upon CpG ODN
stimulation could be detected for IL-6 (20.0 pg/ml [IQR 13.3–30.3 pg/ml] ver-
sus 498.3 pg/ml [IQR 364.5–554.4 pg/ml]; P = 0.028), for IL-10 (0.0 pg/ml [IQR
0.0–0.2 pg/ml] versus 8.5 pg/ml [IQR 0.6–9.5 pg/ml]; P = 0.043) and for TNF-α
(0.0 pg/ml [IQR 0.0–0.2 pg/ml] versus 20.0 pg/ml [IQR 15.7–26.3 pg/ml]; P =
0.028) (median concentration without CpG ODN versus median concentra-
tion with CpG ODN). No differences were seen in the levels of IL-1-β, TGF-β,
IL-12/IL-23, and G-CSF after CpG ODN stimulation. n = 6; boxes show inter-
quartile range and median, whiskers show lowest or highest value; *P < 0.05
using the Wilcoxon signed-rank test. (TIF 2312 kb)
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